Oncology, AI, genomics, proteomics, radiomics, ML, diagnostics

Digitalis Ventures

Accomplice

KdT Ventures

BlueCross BlueShield Venture Partners

T. Chen Fong

Frederic Kerrest

Jonathan J. Fleming

Stanley M. Marks

The Blue Venture Fund

Action Potential Venture Capital

Life Extension Ventures

MassMutual

Onc.AI

We're absolutely thrilled to announce Kevin Masukawa Ph.D. has been appointed Chief Commercial Officer at Onc.AI -- where he'll lead Sales, Marketing and Market-Access organizations. Kevin brings significant oncology sales and strategic marketing experience with past tenures at L.E.K, Genentech (12+ years) and most recently as VP Oncology Marketing at Natera where he architected and executed the market adoption strategy for the breakthrough Signatera test for Molecular Residual Disease (MRD) in solid tumors.  Kevin holds a PhD in Chemical Biology from UCSF and BSc in Biochemistry from UCSD.

If you are at ASCO today, join us now for our last poster session presented by Dr. George Simon, and following discussion at 4:30pm to learn more about care delivery and regulatory policy.

📚 Abstract Title: "AI-based radiomic biomarkers to predict PD-(L)1 immune checkpoint inhibitor response within PD-L1 high/low/negative expression categories in stage IV NSCLC."
🗓️ Poster Session Display Date and Time:
6/5/2023, 1:15 PM-4:15 PM
📍 Poster Board Number: 111

🗣️ Poster Discussion Session Date and Time:
6/5/2023, 4:30 PM-6:00 PM
🎙️ Session Type/Title: Poster Discussion Session - Care Delivery and Regulatory Policy

Don't miss this exciting opportunity to explore the innovative research on AI-based radiomic biomarkers and their potential to predict PD-(L)1 immune checkpoint inhibitor response in stage IV NSCLC patients across different PD-L1 expression categories!

#ASCO2023 #NSCLC #AIinMedicine #Immunotherapy 

Good morning ☀  If you are in Chicago at #ASCO2023, we invite you to attend an exciting poster session this morning: join us to explore the remarkable findings presented by Dr. Chiharu Sako in the field of non-small cell metastatic lung cancer.

Poster Details:
🔍 Temporary Abstract Submission ID: 418076
📑 Abstract Number for Publication: 9124
📚 Abstract Title: "Multi-center real-world data curation and assessment of tumor growth rate and overall survival in advanced NSCLC treated with PD-(L)1 immune checkpoint inhibitor therapy."
🗓️ Session Date and Time:
6/4/2023, 8:00 AM-11:00 AM

Don't miss this opportunity to delve into the latest advancements in the management of advanced NSCLC and engage in meaningful discussions, exchange knowledge, and connect with fellow professionals in the field.

#ASCO2023 #LungCancerResearch #NSCLC  #MedicalAdvancements

Join us at #ASCO2023 to learn about our AI-powered clinical management products. Don't miss our abstract presentations: 

📌 Abstract #9124, Poster #112 (Chiharu Sako, PhD -- Onc.AI) 
📌 Abstract #1517, Poster #111 (George R. Simon, MD, FACP, FCCP -- Moffitt Cancer Center)

Additionally, we're hosting an exclusive gathering on Sunday at 6:30pm for our friends, clinical advisors and partners with limited spots available. 

Calling medical oncologists interested in AI and immunotherapy-focused clinical management solutions. Reach out to contact@onc.ai with "High Spirits" in the subject line and we'll follow-up to get you in! 

Experience the future of oncology with us at #ASCO2023!

#OncologyInnovation #AIinMedicine #ClinicalManagement #Immunotherapy

ONC.AI is a healthcare technology company specializing in the development of AI-driven solutions for oncology and cancer care.

ONC.AI

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Feb 6, 2024 9:06 AM	1d0ad138
translate crunchbase fundingrounds	general
peers	general	Feb 6, 2024 9:06 AM	d6047a6b
news basic	general
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

AI:ONC

ONC.AI